NMS · Analyst Forecast

Monte Rosa Therapeutics, Inc. (GLUE) Analyst Forecast

$10.43 NMS: GLUE Market Cap $889.39M

Revenue and earnings estimates published by analysts covering Monte Rosa Therapeutics, Inc. (GLUE), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Monte Rosa Therapeutics, Inc., analysts forecast revenue rising from $136.47T in 2025 to $143.17T in 2030; the average estimate for 2030 earnings per share is $-2.17; with published estimates ranging from $-6.75 to $-0.11; 7 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

Measure	Value
Current priceWhat the share trades at now.	$10.43
Consensus targetThe average of the price targets analysts have published.	$24.83
Median targetThe middle target, less affected by a single outlier.	$25.00
Highest targetThe most optimistic published target.	$28.00
Lowest targetThe most pessimistic published target.	$19.00
Difference from priceHow far the consensus target sits from today’s price.	+138.1%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

Year	Low	Average	High	Analysts
2025	$132.39T	$136.47T	$140.81T	5
2026	$22.93T	$68.68T	$140.24T	7
2027	$20.58T	$64.61T	$190.05T	7
2028	$33.70T	$124.57T	$326.69T	7
2029	$33.39T	$123.41T	$323.64T	3
2030	$38.73T	$143.17T	$375.46T	5

Earnings per share forecast

Year	Low	Average	High	Analysts
2025	$-0.32	$-0.26	$-0.19	5
2026	$-2.15	$-1.46	$-0.49	7
2027	$-2.65	$-1.86	$0.29	7
2028	$-3.00	$-1.66	$0.91	7
2029	$-6.96	$-2.24	$-0.12	3
2030	$-6.75	$-2.17	$-0.11	5

Monte Rosa Therapeutics, Inc. (GLUE) forecast — frequently asked questions

What is the analyst price target for Monte Rosa Therapeutics, Inc.?

Analysts covering Monte Rosa Therapeutics, Inc. (GLUE) have a consensus price target of $24.83, 138.1% above the current price of $10.43. Published targets range from $19.00 to $28.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Monte Rosa Therapeutics, Inc.'s earnings?

The average analyst estimate for Monte Rosa Therapeutics, Inc. (GLUE) earnings per share in 2030 is -2.17, with individual estimates between -6.75 and -0.11.

How much revenue is Monte Rosa Therapeutics, Inc. expected to make?

Analysts forecast Monte Rosa Therapeutics, Inc. (GLUE) revenue of $143.17T in 2030, based on 5 published estimates.

How many analysts cover GLUE?

7 analysts contribute estimates for Monte Rosa Therapeutics, Inc. (GLUE). Thin coverage makes an average less reliable.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.